Clinical Trial of Rasagiline in Levodopa-Treated Parkinson's Disease Patients With Motor Fluctuations

Inclusion Criteria: * Patients with idiopathic PD * Patients receiving at least 300 mg daily doses of levodopa and not less than 8 daily doses of levodopa with the stable dose * Patient with a Modified Hoehn and Yahr stage between 2 to 4 in the OFF state * Patient with motor fluctuations averaging at least 2 hour daily in the OFF state * Patients who have demonstrated the ability to keep accurate 24-hour diaries Exclusion Criteria: * Patients with Parkinsonian syndrome induced by medicine, metabolic disease, Encephalitis and central nervous system degenerative diseases or Disease of basal ganglia * Patients with severe cognitive impairment judged by a Mini Mental State Examination * Patients with a clinically significant psychiatric illness * Patients with Hamilton Depression Rating Scale (HAMD): total score ≤10 * Patients with a clinically significant or unstable medical or surgical condition which would preclude safe and complete study participation * Patients with a clinically significant or unstable vascular disease * Patients with severe disabling dyskinesias Other inclusion and exclusion criteria may apply